Ocuphire Pharma, Inc. (OCUP)
$3.48
Rating:
Recommendation:
-
| Symbol | OCUP |
|---|---|
| Price | $3.48 |
| Beta | -0.059 |
| Volume Avg. | 0.27M |
| Market Cap | 72.408M |
| Shares () | - |
| 52 Week Range | 1.78-4.43 |
| 1y Target Est | - |
| DCF Unlevered | OCUP DCF -> | |
|---|---|---|
| DCF Levered | OCUP LDCF -> | |
| ROE | -135.62% | Strong Sell |
| ROA | -153.53% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 22.66% | Neutral |
| P/E | - | |
| P/B | 6.01 | Strong Buy |
Latest OCUP news
About
Download (Excel)Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.